LABD reversal to bullishLABD seems to have reached bottom on daily chart and will revers to bullish - see multiple RSI bottoms trending up. I expect the move up to continue for multiple days.
LongLABD
Long
XBI biotech ETF EW count optionsSharing an intermediate view of the EW count options for XBI.
The short-term bullish range is $97-$98.
The short-term bearish target ranges are $89 - $88.50 and $87.
The bearish count, in red, drops the price to $81ish as first support. If, $81 range does not hold, $72 is the C wave target.
In the meantime, I anticipate a lot of chop in the range from $86 - $100 in the next couple months until a rate cut occurs.
As speculation of a rate cut increases, the price can begin to gravi
XBI the ETF for Biotechnology LONGBiotechnology is expected to be a hot subsector this year as healthcare recovered further from
the COVID pandemic anything from startups to big pharma- from vaccines to new drugs for
diabetes, liver disease and obesity. This is shown on a weekly chart to show the long term trend
with XBI pivoting to bullish back in early November. I add long positions when I see a dip
on the 3-4hr chart. My targets are the fib retracement expectation at 116 confluent with
the first upper VWAP band line a
Long
LABU a 3X leveraged ETF of biotechnology stocks LONGLABU on a 240-minute chart has been in a trend up gaining 100% in 3 months. Both the fast and
slow ( green and red) are above the 50 level. Biotechnology is expected to be a hot subsector
this year as healthcare recovered further from the COVID pandemic anything from startups to
big pharma- from vaccines to new drugs for diabetes, liver disease and obesity. Leveraged
funds have time decay from the leveraging and management fees and are meant to be for
short-term trading. Nonetheless,
Long
LABU / LABD Ratio Anchored VWAP over /under LABU LONGOn the weekly chart a LABU / LABD ratio is plotted with anchored VWAP bands and a volume
profile overlaid. I wanted to analyze this to affirm the highest of prospects for the
Biotechnology sector for 2024. LABU is triple leveraged Up while LABD is the inverse Down.
A good unleveraged biotech ETF is XBI. The chart shows LABU in a VWAP band and breakout
through the hohg volume area and then over it beginning early November. Unusually high
relative volume and volatility ramped up abou
Long
Strong bullish case for $LABDCan see this at $15.00 given that is where most shares are currently held, according to FRVP; this means there will likely be little downwards price pressure until then. Biotech is generally bearish outside of select, short-lived bull runs - this, in my opinion, creates an opportunity for sentiment arbitrage and is my reasoning for the trade (short term/long term outlooks are both bearish)
Long
LABU / LABD Medical Leveraged ETFs Flip Strategy.LABU is shown here on a 2H time frame. I am holding 500 shares having bought November 14th
on golden cross of fast and slow hull moving averages. The unrealized gain is 50%.
Here, I determine that I should en bloc or in increments close the position.
First, on the dual time RSI indicator of Chris Moody, the RSI is now over 60 and approaching
65. Price pivoted when RSI was in this range as shown by the red down arrows on the chart.
A fibonacci analysis is that the LABU downtrend of ea
Long
FULC fades after a big move for a SHORT tradeFULC a biotechnology firm with a mixed earnings report early in the month just
printed a big move and then stalled at the NY lunch - hour and faded. Will the fade
continue or will there be an upward continuation? The 15 -minute chart seems to suggest
a downtrend:
1, The volume profile shows heavy trading at the top. This could be short sellers and
late-coming long trades. Once a trend down is underway, the short sellers will begin to
take profits buying to cover while the long trades will
Short
LABD 3X BEAR BIOTECH LONG DAYTRADEAs shown on the 15-minute chart, LABD is bouncing between stardard deviations of the VWAP in a 6% price range
fluctuation day to day. At the upper end it is reversing at the POC of the volume profile confluent with one
standard deviation above VWAP while at the bottom it is bouncing from the bottom of the lower high volume area
of the profile and two standard deviations below VWAP. I see this as an opportunity for a 6% upside long day
trade especially if the general market is uptrendi
Long
(WARNNG) Extreme Bear Volume in $XLF, Shorting next hourly LH- QQQ double topped with Tuesday top, had a 15m bull flag during consolidation with no red flags until mid morning.
- XLF increasing bear volume with zero bounce and very notable big money exiting. Fear creeped into the market
- VIX up 20%
- QQQ went from lead bull to bear when all sectors starting to drop at the same time after XLFs huge drop. dragging SPY down too.
- lots of negative news and sentiment regarding banks and how much they dropped SI down over 80% in just two days.
- Bears
Short
Fast trade on LABDLabd reached a support area where there will be a strong buyer
Entry is done by putting a stoploss as shown in the graph .
For further more wait for our updates .
Short
LABU 3X LEVERAGED BIOTECH ETF on support for LONGAMEX:LABU
LABU a 3x leveraged EFT in the biotechnology sector has diverse holdings.
My thesis is that biotechnology and healthcare are relatively unhinged from the broader general market.
On this 15 minute chart, consolidation at support is seen in July, Price then rapidly rose
into a triple top in mid-August followed by a descent into a double bottom at the support level.
This is a leveraged ETF with good volatility which can be traded.
The volume profile of July through mid-August s
Long
LABU 3X Leverage BIOTECHNOLOGY a potential Recession playLABU a 3x leveraged EFT in the biotechnology sector has diverse holdings.
My thesis is that biotechnology and healthcare are relatively unhinged from the broader general market.
Here I chart LABU / QQQ ratio to determine relative strength.
On this weekly chart, the ratio and so relative strength are at more than a 52 week low.
The MACD indicator shows the MACD and signal line ascending and below the histogram.;
moreover the MACD in green is running above the signal line. This favors a trend
Long
LABU LEVERAGED BIOTECH ETFThis Daily Chart plots LABU to LABD ratios over time. LABU is 3X Leveraged ETF of a variety of biotechnology
stocks while LABD is the inverse.
By plotting the ratio of LABU to LABD, what can be found is the precise end of the LABU downtrend (LABD uptrend)
and reversal into LABU uptrend ( LABD downtrend).
In this case, the reversal occurred about June 17th while the SPY reached its current market bottom.
This type of analysis can be used to make trade decisions regarding a contrasting pair
looking for 83.50 then short off of D legtook a small position on labu at 7.77, looking for 83.50 then short off of D leg
Long
looking for pop, then retest to 73.50 areaseeing bearish pattern set up, a pop then retrace near the .236 fib line
Short
It's a small trendline break but I'll take it.I took a small CALL option position this morning. Got the 5/13 $8 calls for $1.20. Now $1.65.
BIIB and PFE both report in the morning.
Long
MRNA Looks ready to roll overMRNA has gone on an absurd run, and the technical setup looks ripe to the short side. It's all over WSB, looks ripe for a slaughter. There is upside risk with a possible FDA approval so trades have to factor that in.
Short
Is LABD looking to break out of this ascending triangle?As far as popular reversal patterns go, ascending triangles are no bottom of the barrel. Although I still am a new trader, I have been committed to the market for just over 1 year. With that said I have been watching LABD/LABU in proximity of market trends. When the overall market is bullish I trade LABU with success. When Market is bearish I trade LABD with success. My number #1 rule is follow the trend. That is why I am bullish on LABD. With the market making irrational highs despite COVID fea
Long
Long
1 Month Vix vs LABD correlationInteresting correlation between VIX and LABD over the last month. Really goes to show how volatility/sentiment is driving LABD right now and not any view of fundamentals. There has also been a tight correlation between LABD and TXN too, but only over the last month. 1Y TXN LABD is not closely correlated.
VIX
LABD
TXN
Long
Biotech Looking a Little Sick: LABDAnother descending triangle has appeared in LABD. My numerous other finds have yielded decent results but we have yet to see a turn in the market indicating a new direction. The play itself might be worth a couple of percent gain but please trade safely. The downturn near the end of Friday's session is forecasting a likely poor Monday opening in addition to the negative news that continues to come out of the ECB and New York.
Long
LABD: Bearish on biotech tomorrowI don't know how other people are feeling but there are a lot of bearish declining wedges appearing in the leveraged ETFs and elsewhere. Makes me wonder what news we're getting between now and then.
Long